Older patients with acute myeloid leukemia (AML) have a small (< 10%) chance of long-term
survival. Despite the treatment of elderly AML patients with intensive chemotherapy, the
survival has not been improved during the last decades.
The purpose of this study is to determine whether frontline therapy with a 10-day decitabine
schedule provides a better survival than standard intensive combination chemotherapy in
elderly AML patients (>= 60 years).
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators:
Gruppo Italiano Malattie EMatologiche dell'Adulto Janssen Pharmaceuticals